Literature DB >> 1424184

Pulsatile growth hormone release in normal women during the menstrual cycle.

A C Faria1, L W Bekenstein, R A Booth, V A Vaccaro, C M Asplin, J D Veldhuis, M O Thorner, W S Evans.   

Abstract

OBJECTIVE: We sought to characterize pulsatile growth hormone (GH) release in normal women during the menstrual cycle and to document possible relationships between such characteristics and concentrations of 17 beta-oestradiol and progesterone.
SUBJECTS: Fifteen women with ostensibly normal menstrual function were studied during the early follicular phase, 15 during the late follicular phase and 15 during the mid-luteal phase of the menstrual cycle.
DESIGN: The phase of the menstrual cycle having been documented, blood samples were obtained from each woman every 10 minutes for 24 hours. MEASUREMENTS: Serum GH was measured in each sample by immunoradiometric assay. Pulsatile GH release was appraised utilizing the objective, statistically-based pulse detection algorithm Cluster.
RESULTS: The mean (+/- SEM) integrated serum GH concentration (mU/l min) in late follicular phase women (5335 +/- 848) was higher than that observed in early follicular phase women (3156 +/- 322; P = 0.032). The integrated GH concentration calculated for mid-luteal phase women (3853 +/- 788) was intermediate between but not statistically different from that observed in early follicular (P = 0.48) and late follicular (P = 0.14) phase women. No differences in GH pulse frequency (pulses/24 hours) were found among early follicular (8.27 +/- 0.55), late follicular (7.93 +/- 0.91) or mid-luteal (8.47 +/- 0.66) phase women. Mean maximal GH pulse amplitude (mU/l) was higher in late follicular phase (8.93 +/- 1.00) than early follicular phase (5.74 +/- 0.67; P = 0.008) and mid-luteal phase (5.76 +/- 0.74; P = 0.008) women. Similarly, incremental GH pulse amplitude (mU/l) was higher in late follicular phase (7.33 +/- 0.83) than early follicular phase (4.68 +/- 0.58; P = 0.005) and mid-luteal phase (4.36 +/- 0.39; P = 0.002) women. No differences in mean pulse widths or in the interpeak valley mean GH concentrations were found among the groups. Multiple regression of each pulse parameter against serum concentrations of testosterone, 17 beta-oestradiol and progesterone revealed a significant (P = 0.045) positive correlation between maximum GH pulse amplitude and oestradiol and a significant (P = 0.04) negative correlation between maximal GH pulse amplitude and progesterone (r = 0.41).
CONCLUSION: These results suggest that late follicular phase concentrations of oestradiol may enhance circulating GH via an amplitude-modulated rather than a frequency-modulated effect on the endogenous GH pulse. Progesterone may blunt this oestrogen-associated effect, thus resulting in the observed mid-luteal phase concentrations of GH. Whether these gonadal hormones act primarily at the hypothalamus and/or anterior pituitary gland remains to be clarified, but the present observations indicate that pulsatile GH release throughout the normal menstrual cycle is significantly amplitude regulated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424184     DOI: 10.1111/j.1365-2265.1992.tb02270.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  25 in total

1.  Dehydroepiandrosterone restoration of growth hormone gene expression in aging female rats, in vivo and in vitro: evidence for actions via estrogen receptors.

Authors:  Mary Iruthayanathan; Yi-Hong Zhou; Gwen V Childs
Journal:  Endocrinology       Date:  2005-09-08       Impact factor: 4.736

2.  Bipotential effects of estrogen on growth hormone synthesis and storage in vitro.

Authors:  Gwen V Childs; Mary Iruthayanathan; Noor Akhter; Geda Unabia; Brandy Whitehead-Johnson
Journal:  Endocrinology       Date:  2004-12-23       Impact factor: 4.736

Review 3.  Estrogen mediated cross talk between the ovary and pituitary somatotrope. Pre-ovulatory support for reproductive activity.

Authors:  Gwen V Childs; Mary Iruthayanathan; Noor Akhter; Brandy W Johnson
Journal:  Mol Cell Endocrinol       Date:  2006-01-27       Impact factor: 4.102

Review 4.  Caloric restriction: impact upon pituitary function and reproduction.

Authors:  Bronwen Martin; Erin Golden; Olga D Carlson; Josephine M Egan; Mark P Mattson; Stuart Maudsley
Journal:  Ageing Res Rev       Date:  2008-02-07       Impact factor: 10.895

5.  Regulation of basal, pulsatile, and entropic (patterned) modes of GH secretion in a putatively low-somatostatin milieu in women.

Authors:  Johannes D Veldhuis; Susan A Hudson; Joy N Bailey; Dana Erickson
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-02       Impact factor: 4.310

6.  Evaluation of growth hormone response to GHRH plus arginine test in children with idiopathic short stature: role of peak time.

Authors:  M Castagno; A Monzani; S Zanetta; G Genoni; E Giglione; R Ricotti; G Bona; F Prodam; S Bellone
Journal:  J Endocrinol Invest       Date:  2018-02-08       Impact factor: 4.256

7.  Aromatized Estrogens Amplify Nocturnal Growth Hormone Secretion in Testosterone-Replaced Older Hypogonadal Men.

Authors:  Ferdinand Roelfsema; Rebecca J Yang; Paul Y Takahashi; Dana Erickson; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2018-12-01       Impact factor: 5.958

8.  Both estrogen receptor α and β stimulate pituitary GH gene expression.

Authors:  Dimiter Avtanski; Horacio J Novaira; Sheng Wu; Christopher J Romero; Rhonda Kineman; Raul M Luque; Fredric Wondisford; Sally Radovick
Journal:  Mol Endocrinol       Date:  2013-01-01

9.  Visceral fat is a negative predictor of bone density measures in obese adolescent girls.

Authors:  Melissa Russell; Nara Mendes; Karen K Miller; Clifford J Rosen; Hang Lee; Anne Klibanski; Madhusmita Misra
Journal:  J Clin Endocrinol Metab       Date:  2010-01-15       Impact factor: 5.958

10.  Gender and age in the biochemical assessment of cure of acromegaly.

Authors:  P U Freda; R E Landman; R E Sundeen; K D Post
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.